title: Antipsychotic treatment in older schizophrenia patients with extrapyramidal side effects in Asia (2001 - 2009).
abstract: OBJECTIVE
  This study surveyed the prescribing patterns of antipsychotic medications in Asian older schizophrenia patients with extrapyramidal side effects (EPS) during the period between 2001 and 2009.
  
  
  METHODS
  Information on 848 hospitalized patients with schizophrenia aged 60 or older was extracted from the database of the Research on Asian Psychotropic Prescription Patterns (REAP) study (2001 - 2009). Data from those patients with reported EPS from 8 Asian countries and territories including China, Hong Kong, Japan, Korea, Singapore, Taiwan, India and Malaysia were analyzed. The cross-sectional data of sociodemographic and clinical characteristics and antipsychotic prescriptions were collected using a standardized protocol and data collection procedure.
  
  
  RESULTS
  Of the 309/848 (36%) patients suffering from EPS, 210 patients (210/309; 68.0%) received at least one type of first generation antipsychotic (FGA), and 99 (99/309; 32.0%) received second generation antipsychotics (SGAs) only. Of SGAs prescribed in patients with EPS, risperidone was the most commonly used (100/309; 32.4%) followed by olanzapine (33/309; 10.7%) and quetiapine (25/309; 8.1%).
  
  
  CONCLUSIONS
  FGAs were frequently used in Asian older schizophrenia patients with EPS. Considering the potential adverse effects of FGAs on existing EPS, the reasons for the frequent use of FGAs need to be urgently identified.
authors.affiliation: Department of Psychiatry, Chinese University of Hong Kong, Hong Kong. xyutly@gmail.com
authors.forename: Yu-Tao
authors.initials: YT
authors.lastname: Xiang
authors.forename: Julie
authors.initials: J
authors.lastname: Kreyenbuhl
authors.forename: Faith B
authors.initials: FB
authors.lastname: Dickerson
authors.forename: Gabor S
authors.initials: GS
authors.lastname: Ungvari
authors.forename: Chuanâ Yue
authors.initials: CY
authors.lastname: Wang
authors.forename: Tian-Mei
authors.initials: TM
authors.lastname: Si
authors.forename: Edwin H M
authors.initials: EH
authors.lastname: Lee
authors.forename: Helen F K
authors.initials: HF
authors.lastname: Chiu
authors.forename: Kelly Y C
authors.initials: KY
authors.lastname: Lai
authors.forename: Yan-Ling
authors.initials: YL
authors.lastname: He
authors.forename: Shu-Yu
authors.initials: SY
authors.lastname: Yang
authors.forename: Mian-Yoon
authors.initials: MY
authors.lastname: Chong
authors.forename: Chay-Hoon
authors.initials: CH
authors.lastname: Tan
authors.forename: Eeâ Heok
authors.initials: EH
authors.lastname: Kua
authors.forename: Senta
authors.initials: S
authors.lastname: Fujii
authors.forename: Kang
authors.initials: K
authors.lastname: Sim
authors.forename: Michael K H
authors.initials: MK
authors.lastname: Yong
authors.forename: Jitendra K
authors.initials: JK
authors.lastname: Trivedi
authors.forename: Eunâ Kee
authors.initials: EK
authors.lastname: Chung
authors.forename: Pichet
authors.initials: P
authors.lastname: Udomratn
authors.forename: Kok-Yoon
authors.initials: KY
authors.lastname: Chee
authors.forename: Norman
authors.initials: N
authors.lastname: Sartorius
authors.forename: Naotaka
authors.initials: N
authors.lastname: Shinfuku
mesh_terms: D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001480:Basal Ganglia Diseases / Q000139:chemically induced*; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents